Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1135

1.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT.

J Clin Psychiatry. 2007 Aug;68(8):1246-56.

PMID:
17854250
2.

Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.

Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB.

J Clin Psychiatry. 2007 Jul;68(7):1014-23.

PMID:
17685736
3.

Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.

Thase ME, Gelenberg A, Kornstein SG, Kocsis JH, Trivedi MH, Ninan P, Li T, Pedersen R, Keller M.

J Psychiatr Res. 2011 Mar;45(3):412-20. doi: 10.1016/j.jpsychires.2010.07.009.

PMID:
20801464
4.

Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.

Kornstein SG.

Expert Rev Neurother. 2008 May;8(5):737-42. doi: 10.1586/14737175.8.5.737. Review.

PMID:
18457530
5.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
7.

Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.

Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, Keller MB.

J Clin Psychiatry. 2014 Jan;75(1):62-8. doi: 10.4088/JCP.12m07841.

PMID:
24345717
8.

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.

Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J.

Arch Gen Psychiatry. 2006 Oct;63(10):1158-65.

PMID:
17015818
11.

Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.

Simon JS, Aguiar LM, Kunz NR, Lei D.

J Psychiatr Res. 2004 May-Jun;38(3):249-57. Erratum in: J Psychiatr Res. 42004 Jul-Aug;38(4):51.

PMID:
15003430
12.

Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release.

Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E.

J Clin Psychiatry. 2007 Jan;68(1):58-68.

PMID:
17284131
13.

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.

Shelton C, Entsuah R, Padmanabhan SK, Vinall PE.

Int Clin Psychopharmacol. 2005 Jul;20(4):233-8.

PMID:
15933485
14.
15.

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.

Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.

Depress Anxiety. 2007;24(1):1-14.

PMID:
16894619
16.

Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.

Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ.

J Clin Psychopharmacol. 2006 Jun;26(3):259-67. Erratum in: J Clin Psychopharmacol. 2006 Oct;26(5):473. Dosage error in article text.

PMID:
16702890
17.
18.

Venlafaxine versus placebo in the preventive treatment of recurrent major depression.

Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL; Venlafaxine 335 Study Group.

J Clin Psychiatry. 2004 Mar;65(3):328-36.

PMID:
15096071
20.

Supplemental Content

Support Center